Effectiveness and Safety of Ustekinumab for Pediatric Inflammatory Bowel Disease: A Systematic Review.
Journal
Paediatric drugs
ISSN: 1179-2019
Titre abrégé: Paediatr Drugs
Pays: Switzerland
ID NLM: 100883685
Informations de publication
Date de publication:
Sep 2023
Sep 2023
Historique:
accepted:
17
07
2023
medline:
11
8
2023
pubmed:
2
8
2023
entrez:
1
8
2023
Statut:
ppublish
Résumé
The use of ustekinumab in pediatric patients with inflammatory bowel disease (IBD) is off-label and the data are limited. We conducted a systematic review evaluating the efficacy and safety of ustekinumab in pediatric IBD. We systematically searched PubMed, EMBASE and Cochrane databases for studies of ustekinumab in children and adolescents with IBD investigating clinical remission, clinical response, corticosteroid-free (CS-free) remission, endoscopic remission/response, or safety up to March 17, 2023. A random-effects model was used for calculating summary estimates. Eleven studies, comprising 370 patients were included. For Crohn's disease (CD), the pooled clinical remission rates were 34% (73/204) at 8-16 weeks and 46% (60/129) at 1 year. The pooled CS-free clinical remission rates were 23% (10/44) at 8-16 weeks and 45% (42/96) at 1 year. For ulcerative colitis (UC)/IBD unspecified (IBD-U), the pooled CS-free clinical remission rates were 24% (6/25) at 26 weeks and 46% (16/35) at 1 year. Endoscopic remission was found in 0-37.5% of CD and 63.6% of UC. Serious adverse events were reported in 3.5% of patients. About one half of patients required reduction in dose intervals and 62.75% patients could continue ustekinumab therapy at 1 year or final visit. According to low-quality evidence mainly from cohort studies and case series, approximately one half of patients with CD and UC/IBD-U achieved remission at 1 year. Ustekinumab has a reasonable safety profile and dose optimization is frequently required. Data on the long-term benefit and high-quality evidence are still needed.
Sections du résumé
BACKGROUND
BACKGROUND
The use of ustekinumab in pediatric patients with inflammatory bowel disease (IBD) is off-label and the data are limited. We conducted a systematic review evaluating the efficacy and safety of ustekinumab in pediatric IBD.
METHODS
METHODS
We systematically searched PubMed, EMBASE and Cochrane databases for studies of ustekinumab in children and adolescents with IBD investigating clinical remission, clinical response, corticosteroid-free (CS-free) remission, endoscopic remission/response, or safety up to March 17, 2023. A random-effects model was used for calculating summary estimates.
RESULTS
RESULTS
Eleven studies, comprising 370 patients were included. For Crohn's disease (CD), the pooled clinical remission rates were 34% (73/204) at 8-16 weeks and 46% (60/129) at 1 year. The pooled CS-free clinical remission rates were 23% (10/44) at 8-16 weeks and 45% (42/96) at 1 year. For ulcerative colitis (UC)/IBD unspecified (IBD-U), the pooled CS-free clinical remission rates were 24% (6/25) at 26 weeks and 46% (16/35) at 1 year. Endoscopic remission was found in 0-37.5% of CD and 63.6% of UC. Serious adverse events were reported in 3.5% of patients. About one half of patients required reduction in dose intervals and 62.75% patients could continue ustekinumab therapy at 1 year or final visit.
CONCLUSIONS
CONCLUSIONS
According to low-quality evidence mainly from cohort studies and case series, approximately one half of patients with CD and UC/IBD-U achieved remission at 1 year. Ustekinumab has a reasonable safety profile and dose optimization is frequently required. Data on the long-term benefit and high-quality evidence are still needed.
Identifiants
pubmed: 37528211
doi: 10.1007/s40272-023-00586-7
pii: 10.1007/s40272-023-00586-7
doi:
Substances chimiques
Ustekinumab
FU77B4U5Z0
Types de publication
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
499-513Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
Références
Jakobsen C, Bartek J Jr, Wewer V, Vind I, Munkholm P, Groen R, et al. Differences in phenotype and disease course in adult and paediatric inflammatory bowel disease—a population-based study. Aliment Pharmacol Ther. 2011;34(10):1217–24.
doi: 10.1111/j.1365-2036.2011.04857.x
pubmed: 21981762
Ben-Horin S, Chowers Y. Review article: loss of response to anti-TNF treatments in Crohn’s disease. Aliment Pharmacol Ther. 2011;33(9):987–95.
doi: 10.1111/j.1365-2036.2011.04612.x
pubmed: 21366636
Roda G, Jharap B, Neeraj N, Colombel JF. Loss of response to anti-TNFs: definition, epidemiology, and management. Clin Transl Gastroenterol. 2016;7(1): e135.
doi: 10.1038/ctg.2015.63
pubmed: 26741065
pmcid: 4737871
Papamichael K, Gils A, Rutgeerts P, Levesque BG, Vermeire S, Sandborn WJ, et al. Role for therapeutic drug monitoring during induction therapy with TNF antagonists in IBD: evolution in the definition and management of primary nonresponse. Inflamm Bowel Dis. 2015;21(1):182–97.
doi: 10.1097/MIB.0000000000000202
pubmed: 25222660
Danese S. New therapies for inflammatory bowel disease: from the bench to the bedside. Gut. 2012;61(6):918–32.
doi: 10.1136/gutjnl-2011-300904
pubmed: 22115827
Sands BE, Sandborn WJ, Panaccione R, O’Brien CD, Zhang H, Johanns J, et al. Ustekinumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2019;381(13):1201–14.
doi: 10.1056/NEJMoa1900750
pubmed: 31553833
Sandborn WJ, Feagan BG, Fedorak RN, Scherl E, Fleisher MR, Katz S, et al. A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn’s disease. Gastroenterology. 2008;135(4):1130–41.
doi: 10.1053/j.gastro.2008.07.014
pubmed: 18706417
Feagan BG, Sandborn WJ, Gasink C, Jacobstein D, Lang Y, Friedman JR, et al. Ustekinumab as induction and maintenance therapy for crohn’s disease. N Engl J Med. 2016;375(20):1946–60.
doi: 10.1056/NEJMoa1602773
pubmed: 27959607
https://www.drugs.com/newdrugs/fda-approves-stelara-ustekinumab-adults-moderately-severely-active-crohn-s-4436.html
https://www.drugs.com/newdrugs/janssen-announces-fda-approval-stelara-ustekinumab-adults-moderately-severely-active-ulcerative-5084.html
Raine T, Bonovas S, Burisch J, Kucharzik T, Adamina M, Annese V, et al. ECCO guidelines on therapeutics in ulcerative colitis: medical treatment. J Crohns Colitis. 2022;16(1):2–17.
doi: 10.1093/ecco-jcc/jjab178
pubmed: 34635919
Torres J, Bonovas S, Doherty G, Kucharzik T, Gisbert JP, Raine T, et al. ECCO guidelines on therapeutics in crohn’s disease: medical treatment. J Crohns Colitis. 2020;14(1):4–22.
doi: 10.1093/ecco-jcc/jjz180
pubmed: 31711158
van Rheenen PF, Aloi M, Assa A, Bronsky J, Escher JC, Fagerberg UL, et al. The medical management of paediatric crohn’s disease: an ECCO-ESPGHAN guideline update. J Crohn’s Colitis. 2020;2:2.
Turner D, Griffiths AM, Wilson D, Mould DR, Baldassano RN, Russell RK, et al. Designing clinical trials in paediatric inflammatory bowel diseases: a PIBDnet commentary. Gut. 2020;69(1):32–41.
doi: 10.1136/gutjnl-2018-317987
pubmed: 30979718
Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7): e1000097.
doi: 10.1371/journal.pmed.1000097
pubmed: 19621072
pmcid: 2707599
Guo B, Moga C, Harstall C, Schopflocher D. A principal component analysis is conducted for a case series quality appraisal checklist. J Clin Epidemiol. 2016;69:199-207.e2.
doi: 10.1016/j.jclinepi.2015.07.010
pubmed: 26307459
Moga C, Guo B, Schopflocher D, Harstall C. Development of a Quality Appraisal Tool for Case Series Studies Using a Modified Delphi Technique. Edmonton AB: Institute of Health Economics, (2012).
Chavannes M, Martinez-Vinson C, Hart L, Kaniki N, Chao CY, Lawrence S, et al. Management of paediatric patients with medically refractory crohn’s disease using ustekinumab: a multi-centred cohort study. J Crohns Colitis. 2019;13(5):578–84.
doi: 10.1093/ecco-jcc/jjy206
pubmed: 30541021
Dayan JR, Dolinger M, Benkov K, Dunkin D, Jossen J, Lai J, et al. Real world experience with ustekinumab in children and young adults at a tertiary care pediatric inflammatory bowel disease center. J Pediatr Gastroenterol Nutr. 2019;69(1):61–7.
doi: 10.1097/MPG.0000000000002362
pubmed: 31058718
pmcid: 7408448
Takeuchi I, Arai K, Kyodo R, Sato T, Tokita K, Hirano Y, et al. Ustekinumab for children and adolescents with inflammatory bowel disease at a tertiary children’s hospital in Japan. J Gastroenterol Hepatol. 2021;36(1):125–30.
doi: 10.1111/jgh.15128
pubmed: 32497325
Dhaliwal J, McKay HE, Deslandres C, Debruyn J, Wine E, Wu A, et al. One-year outcomes with ustekinumab therapy in infliximab-refractory paediatric ulcerative colitis: a multicentre prospective study. Aliment Pharmacol Ther. 2021;53(12):1300–8.
doi: 10.1111/apt.16388
pubmed: 33909911
Dolinger MT, Spencer EA, Lai J, Dunkin D, Dubinsky MC. Dual biologic and small molecule therapy for the treatment of refractory pediatric inflammatory bowel disease. Inflamm Bowel Dis. 2021;27(8):1210–4.
doi: 10.1093/ibd/izaa277
pubmed: 33125058
Kim FS, Patel PV, Stekol E, Ali S, Hamandi H, Heyman MB, et al. Experience using ustekinumab in pediatric patients with medically refractory crohn disease. J Pediatr Gastroenterol Nutr. 2021;73(5):610–4.
doi: 10.1097/MPG.0000000000003230
pubmed: 34415711
pmcid: 8542638
Do P, Andersen J, Patel A, Semrin G, Sifuentes-Dominguez L, Luu P, et al. Augmented ustekinumab dosing is needed to achieve clinical response in patients with anti-TNF refractory pediatric Crohn’s disease: a retrospective chart review. F1000Research. 2020;9:316.
doi: 10.12688/f1000research.22673.1
pubmed: 34504690
Cohen A, Ahmed N, Sant’Anna A. Ustekinumab for the treatment of refractory pediatric Crohn’s disease: a single-center experience. Intestinal Res. 2021;19(2):217–24.
doi: 10.5217/ir.2019.09164
Rosh JR, Turner D, Griffiths A, Cohen SA, Jacobstein D, Adedokun OJ, et al. Ustekinumab in paediatric patients with moderately to severely active crohn’s disease: pharmacokinetics, safety, and efficacy results from unistar, a phase 1 study. J Crohns Colitis. 2021;15(11):1931–42.
doi: 10.1093/ecco-jcc/jjab089
pubmed: 34037715
pmcid: 8575045
Yerushalmy-Feler A, Pujol-Muncunill G, Martin-de-Carpi J, Kolho KL, Levine A, Olbjørn C, et al. Safety and potential efficacy of escalating dose of ustekinumab in pediatric crohn disease (the Speed-up Study): a multicenter study from the pediatric IBD Porto group of ESPGHAN. J Pediatr Gastroenterol Nutr. 2022;75(6):717–23.
doi: 10.1097/MPG.0000000000003608
pubmed: 36084231
Koudsi M, Martinez-Vinson C, Pigneur B, Willot S, Djamal D, Enaud R, et al. Ustekinumab use in pediatric inflammatory bowel disease: a French multicenter study from the pediatric GETAID. J Pediatr Gastroenterol Nutr. 2023;2:2.
Bermejo F, Jiménez L, Algaba A, Vela M, Bastida G, Merino O, et al. Re-induction with intravenous ustekinumab in patients with crohn’s disease and a loss of response to this therapy. Inflamm Bowel Dis. 2022;28(1):41–7.
doi: 10.1093/ibd/izab015
pubmed: 33528018
Iborra M, Beltrán B, Fernández-Clotet A, Iglesias-Flores E, Navarro P, Rivero M, et al. Real-world long-term effectiveness of ustekinumab in Crohn’s disease: results from the ENEIDA registry. Aliment Pharmacol Ther. 2020;52(6):1017–30.
pubmed: 32770851
Forss A, Clements M, Myrelid P, Strid H, Söderman C, Wagner A, et al. Ustekinumab is associated with real-world long-term effectiveness and improved health-related quality of life in crohn’s disease. Dig Dis Sci. 2023;68(1):65–76.
doi: 10.1007/s10620-022-07501-z
pubmed: 35459973
Casas-Deza D, Lamuela-Calvo LJ, Gomollón F, Arbonés-Mainar JM, Caballol B, Gisbert JP, et al. Effectiveness and safety of ustekinumab in elderly patients with crohn’s disease: real world evidence from the ENEIDA registry. J Crohns Colitis. 2023;17(1):83–91.
doi: 10.1093/ecco-jcc/jjac108
pubmed: 35913456
Taxonera C, Olivares D, López-García ON, Alba C. Meta-analysis: real-world effectiveness and safety of ustekinumab in patients with ulcerative colitis. Aliment Pharmacol Ther. 2023;57(6):610–9.
doi: 10.1111/apt.17386
pubmed: 36645145
Rubín de Célix C, Chaparro M, Gisbert JP. Real-world evidence of the effectiveness and safety of ustekinumab for the treatment of crohn's disease: systematic review and meta-analysis of observational studies. J Clin Med. 2022;11:14
Yang H, Li B, Guo Q, Tang J, Peng B, Ding N, et al. Systematic review with meta-analysis: loss of response and requirement of ustekinumab dose escalation in inflammatory bowel diseases. Aliment Pharmacol Ther. 2022;55(7):764–77.
doi: 10.1111/apt.16802
pubmed: 35141914
Casas Deza D, García López S, Lafuente Blasco M, Vicente Lidón R, Nerín de la Puerta J, Peña Gonzalez E, et al. Efficacy and safety of ustekinumab in real clinical practice. Retrospective multicentre study. ARAINF cohort. Gastroenterologia y hepatologia. 2020;43(3):126-32.
Parra RS, Chebli JMF, Queiroz NSF, Damião A, de Azevedo MFC, Chebli LA, et al. Long-term effectiveness and safety of ustekinumab in bio-naïve and bio-experienced anti-tumor necrosis factor patients with Crohn’s disease: a real-world multicenter Brazilian study. BMC Gastroenterol. 2022;22(1):199.
doi: 10.1186/s12876-022-02280-3
pubmed: 35448949
pmcid: 9027080
Ma C, Fedorak RN, Kaplan GG, Dieleman LA, Devlin SM, Stern N, et al. Clinical, endoscopic and radiographic outcomes with ustekinumab in medically-refractory Crohn’s disease: real world experience from a multicentre cohort. Aliment Pharmacol Ther. 2017;45(9):1232–43.
doi: 10.1111/apt.14016
pubmed: 28252210
Ma C, Fedorak RN, Kaplan GG, Dieleman LA, Devlin SM, Stern N, et al. Long-term maintenance of clinical, endoscopic, and radiographic response to ustekinumab in moderate-to-severe crohn’s disease: real-world experience from a multicenter cohort study. Inflamm Bowel Dis. 2017;23(5):833–9.
doi: 10.1097/MIB.0000000000001074
pubmed: 28328624
Kubesch A, Rueter L, Farrag K, Krause T, Stienecker K, Hausmann J, et al. Short and Long-term effectiveness of ustekinumab in patients with crohn’s disease: real-world data from a German IBD cohort. J Clin Med. 2019;8:12.
doi: 10.3390/jcm8122140